You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆瑞醫藥(600276.SH):獲得鹽酸伊立替康脂質體注射液、SHR-1701注射液的藥物臨牀試驗批准通知書
格隆匯 09-28 16:04

格隆匯9月28日丨恆瑞醫藥(600276.SH)公佈,近日,公司及子公司蘇州盛迪亞生物醫藥有限公司收到國家藥品監督管理局核准簽發關於鹽酸伊立替康脂質體注射液、SHR-1701注射液的《藥物臨牀試驗批准通知書》,將於近期開展臨牀試驗。

鹽酸伊立替康是喜樹鹼的半合成衍生物。喜樹鹼可特異性地與拓撲異構酶I結合,後者誘導可逆性單鏈斷裂,從而使DNA雙鏈結構解旋;鹽酸伊立替康及其活性代謝物SN-38可與拓撲異構酶I-DNA複合物結合,從而阻止斷裂單鏈的再連接。

經查詢,伊立替康相關劑型2020年全球總銷售額約為6.88億美元。截至目前,鹽酸伊立替康脂質體注射液相關研發項目累計已投入研發費用約為8675萬元。

SHR-1701可以促進效應性T細胞的活化,同時還可有效改善腫瘤微環境中的免疫調節作用,最終有效促進免疫系統對於腫瘤細胞的殺傷。SHR-1701注射液已在中國開展多項實體瘤臨牀試驗,並在澳洲開展I期臨牀試驗。

經查詢,MerckKGaA公司、普米斯生物技術、蘇州創勝集團、博際生物醫藥、齊魯製藥、友芝友的同類產品在國內外處於臨牀試驗階段,適應症以晚期惡性腫瘤為主。國內外尚無同類產品獲批上市,亦無相關銷售數據。截至目前,SHR-1701相關項目累計已投入研發費用約為2.22億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account